Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.62 USD | -1.91% | +3.60% | -7.98% |
05:57pm | Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $21 From $36, Maintains Overweight Rating | MT |
15/05 | Transcript : Abeona Therapeutics Inc., Q1 2024 Earnings Call, May 15, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.98% | 187M | |
+33.58% | 49.46B | |
+1.54% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.59% | 26.61B | |
-20.92% | 18.64B | |
+7.41% | 13.16B | |
+28.38% | 12.55B | |
+23.86% | 12.1B |
- Stock Market
- Equities
- ABEO Stock
- News Abeona Therapeutics Inc.
- Abeona Therapeutics Says FDA Grants Priority Review for BLA to Treat Rare Connective Tissue Disorder; Shares Jump